A phase I, randomised, double-blind, placebo controlled, dose ranging study to evaluate the safety, tolerability and pharmacokinetics of EMA401 following multiple oral dosing in healthy male subjects.

Trial Profile

A phase I, randomised, double-blind, placebo controlled, dose ranging study to evaluate the safety, tolerability and pharmacokinetics of EMA401 following multiple oral dosing in healthy male subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs EMA 401 (Primary)
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Adverse reactions
  • Sponsors Spinifex Pharmaceuticals
  • Most Recent Events

    • 31 Aug 2012 Results presented at the 14th World Congress on Pain.
    • 24 Jun 2009 Status changed from not stated to recruiting.
    • 24 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top